Ascentage Pharma recently unveiled promising clinical data on the use of Alrizomadlin as a monotherapy and in combination therapies for solid tumors at ASCO 2025. The presentation highlighted the company’s optimistic outlook and strategic plans for future developments in the pharmaceutical industry. Ascentage Pharma’s forward-looking statements, as per the regulations, express the company’s views on […]
Tag: pharma
Nxera Pharma Receives $15 Million from Neurocrine Biosciences for Phase 3 Trial of NBI-1117568
In a significant development, Nxera Pharma Group has secured a substantial investment of $15 million from Neurocrine Biosciences following the dosing of the first patient in the Phase 3 trial of NBI-1117568. This strategic alliance marks a crucial milestone in the discovery, development, and potential commercialization of innovative pharmaceutical products. However, investors should be aware […]
Piramal Pharma Canada Unit Receives NAI from USFDA
Piramal Pharma Limited’s stock surged after the announcement that the US Food and Drug Administration (USFDA) granted a Form 483 with zero observations and a No Action Indicated (NAI) status for its Aurora facility in Canada. This regulatory approval signifies the facility’s compliance with stringent quality standards, paving the way for potential market expansion and […]
